| Name | Title | Contact Details |
|---|
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development.
The MBX Difference: Relationship Based Partnerships Our bottom line in your bottom line. We don`t simply chase the low-hanging fruit. Put simply, our outsourced revenue cycle management will collect more dollars, improve your cash flow, support your physicians and delight your patients. MBX is a growing organization specializing in radiology billing. With MBX, from the start of our relationship to go live, you are in safe hands. Our experienced leadership team, who between them possess over seven decades of working with some of the nation’s leading radiology group practices, has implemented over 300 outsourced revenue cycle management systems. We process millions of procedures per year for practices from coast to coast, as diverse as three provider interventional radiologists in Oregon to a 100+ provider practice in North Carolina. MBX delivers consistent and exceptional revenue cycle management. We bill and collect every possible dollar by capitalizing on operational expertise that is second to none. Our exceptional rate of claims accepted the first time, along with our strong denials management process, ensures that claims are processed quickly and denials handled efficiently and effectively. Our end-to-end service extends from the point at which we receive the physician’s dictated report all the way through to the patient’s account at zero balance – we worry about the billing, you lower your operational overheads.
AAAT.L.C Healthcare is a Encino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hydrogen Health is a virtual primary care solution that brings K Healths suite of digital healthcare services to employers and health plans, increasing positive long term health outcomes while substantially reducing costs.
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.